L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP
Conditions: Severe Obesity; Type 2 Diabetes Mellitus in Obese Intervention: Other: Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells. Sponsor: University of Sao Paulo General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 6, 2022 Category: Research Source Type: clinical trials
Evaluation of L-Cell Activity in the Small Intestine as Biliopancreatic Loop Extension in Obese Patients With DM2 Submitted to Roux-en-Y Gastric Bypass
Conditions: Severe Obesity; Type 2 Diabetes Mellitus in Obese Intervention: Other: Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells. Sponsor: University of Sao Paulo General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 6, 2022 Category: Research Source Type: clinical trials
To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
Condition: Diabetes Mellitus, Type 2 Interventions: Drug: empagliflozin; Drug: Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 17, 2021 Category: Research Source Type: clinical trials
